Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Holly M Nguyen

Showing results (31-40 of 45) with videos related to

Pageof 5
Sort By:
Cancer Research Communications|October 12, 2023
Concurrent Targeting of HDAC and PI3K to Overcome Phenotypic Heterogeneity of Castration-resistant and Neuroendocrine Prostate CancersAilin Zhang, Nathan A Lau, Alicia Wong, et al.
JCI Insight|May 23, 2022
Response to supraphysiological testosterone is predicted by a distinct androgen receptor cistromeXintao Qiu, Lisha G Brown, Jennifer L Conner, et al.
The Journal of Clinical Investigation|July 31, 2019
Molecular profiling stratifies diverse phenotypes of treatment-refractory metastatic castration-resistant prostate cancerMark P Labrecque, Ilsa M Coleman, Lisha G Brown, et al.
Neoplasia (New York, N.Y.)|May 30, 2026
Systematic analysis of hippo pathway signaling identifies TEAD1 as a transcriptional regulator of neuroendocrine prostate cancerLisha G Brown, Ilsa M Coleman, Tony L H Chu, et al.
Scientific Reports|November 24, 2018
High-throughput screens identify HSP90 inhibitors as potent therapeutics that target inter-related growth and survival pathways in advanced prostate cancerKeith H Jansson, John B Tucker, Lauren E Stahl, et al.
Medrxiv : the Preprint Server for Health Sciences|March 3, 2023
Enhancer profiling identifies epigenetic markers of endocrine resistance and reveals therapeutic options for metastatic castration-resistant prostate cancer patientsTesa M Severson, Yanyun Zhu, Stefan Prekovic, et al.
Cancer Cell|October 11, 2017
Androgen Receptor Pathway-Independent Prostate Cancer Is Sustained through FGF SignalingEric G Bluemn, Ilsa M Coleman, Jared M Lucas, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 19, 2024
Small-molecule disruption of androgen receptor-dependent chromatin clustersSarah E Kohrt, Emily J Novak, Subhashish Tapadar, et al.
Cell Reports. Medicine|July 3, 2025
Epigenetic profiling identifies markers of endocrine resistance and therapeutic options for metastatic castration-resistant prostate cancerTesa M Severson, Emma Minnee, Yanyun Zhu, et al.
Cell Reports. Medicine|January 20, 2024
UCHL1 is a potential molecular indicator and therapeutic target for neuroendocrine carcinomasShiqin Liu, Timothy Chai, Fernando Garcia-Marques, et al.
Pageof 5

Showing results (31-40 of 45) with videos related to

Sort By:
Pageof 5
Cancer Research Communications|October 12, 2023
Concurrent Targeting of HDAC and PI3K to Overcome Phenotypic Heterogeneity of Castration-resistant and Neuroendocrine Prostate CancersAilin Zhang, Nathan A Lau, Alicia Wong, et al.
JCI Insight|May 23, 2022
Response to supraphysiological testosterone is predicted by a distinct androgen receptor cistromeXintao Qiu, Lisha G Brown, Jennifer L Conner, et al.
The Journal of Clinical Investigation|July 31, 2019
Molecular profiling stratifies diverse phenotypes of treatment-refractory metastatic castration-resistant prostate cancerMark P Labrecque, Ilsa M Coleman, Lisha G Brown, et al.
Neoplasia (New York, N.Y.)|May 30, 2026
Systematic analysis of hippo pathway signaling identifies TEAD1 as a transcriptional regulator of neuroendocrine prostate cancerLisha G Brown, Ilsa M Coleman, Tony L H Chu, et al.
Scientific Reports|November 24, 2018
High-throughput screens identify HSP90 inhibitors as potent therapeutics that target inter-related growth and survival pathways in advanced prostate cancerKeith H Jansson, John B Tucker, Lauren E Stahl, et al.
Medrxiv : the Preprint Server for Health Sciences|March 3, 2023
Enhancer profiling identifies epigenetic markers of endocrine resistance and reveals therapeutic options for metastatic castration-resistant prostate cancer patientsTesa M Severson, Yanyun Zhu, Stefan Prekovic, et al.
Cancer Cell|October 11, 2017
Androgen Receptor Pathway-Independent Prostate Cancer Is Sustained through FGF SignalingEric G Bluemn, Ilsa M Coleman, Jared M Lucas, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 19, 2024
Small-molecule disruption of androgen receptor-dependent chromatin clustersSarah E Kohrt, Emily J Novak, Subhashish Tapadar, et al.
Cell Reports. Medicine|July 3, 2025
Epigenetic profiling identifies markers of endocrine resistance and therapeutic options for metastatic castration-resistant prostate cancerTesa M Severson, Emma Minnee, Yanyun Zhu, et al.
Cell Reports. Medicine|January 20, 2024
UCHL1 is a potential molecular indicator and therapeutic target for neuroendocrine carcinomasShiqin Liu, Timothy Chai, Fernando Garcia-Marques, et al.
Pageof 5